Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03893890 · ClinicalTrials.gov registry record
Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
A clinical trial, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- 8
- Enrollment target
NCT03893890: Completed study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT03893890 is a clinical trial that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03893890 has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This is a Phase 2b, rollover, long-term study to evaluate the safety and duration of efficacy of EN3835 in the treatment of women with EFP. Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in study EN3835-201 will be eligible for this study.
Interventions
- BIOLOGICAL Previously Treated with EN3835
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2019-06-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03893890
The ClinicalTrials.gov registry entry for NCT03893890 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Previously Treated with EN3835 is the first listed.
NCT03893890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03893890 about?
NCT03893890 is a clinical study titled "Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women". This is a Phase 2b, rollover, long-term study to evaluate the safety and duration of efficacy of EN3835 in the treatment of women with EFP. Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS ...
What is the current status of trial NCT03893890?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2019-03-28. Estimated completion is 2019-06-25.
What interventions are being tested in trial NCT03893890?
The interventions under investigation include: Previously Treated with EN3835 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03893890?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.